|
|
|
ix | |
| Acknowledgements |
|
xi | |
| Introduction |
|
xiii | |
| About the companion website |
|
xvi | |
|
1 Epidermal growth factor receptor family |
|
|
1 | (24) |
|
|
|
1.1 ErbB receptors and their structure |
|
|
1 | (1) |
|
|
|
2 | (3) |
|
1.3 Downstream signalling molecules and events |
|
|
5 | (3) |
|
1.4 Signalling regulation |
|
|
8 | (2) |
|
1.5 Dysregulation of signalling in cancer |
|
|
10 | (3) |
|
1.6 Therapeutic opportunities |
|
|
13 | (12) |
|
|
|
17 | (8) |
|
2 Insulin and the insulin-like growth factor (IGF) family |
|
|
25 | (20) |
|
|
|
|
|
|
|
|
|
25 | (3) |
|
|
|
28 | (2) |
|
2.3 Downstream signalling molecules and events |
|
|
30 | (2) |
|
2.4 Dysregulation of signalling in cancer |
|
|
32 | (2) |
|
2.5 Therapeutic opportunities |
|
|
34 | (11) |
|
|
|
37 | (8) |
|
3 Transforming growth factor- β receptor signalling |
|
|
45 | (22) |
|
|
|
|
|
45 | (3) |
|
|
|
48 | (1) |
|
3.3 Downstream signalling molecules and events |
|
|
49 | (4) |
|
3.4 Signalling regulation |
|
|
53 | (3) |
|
3.5 Dysregulation of signalling in cancer |
|
|
56 | (2) |
|
3.6 Therapeutic opportunities |
|
|
58 | (9) |
|
|
|
60 | (7) |
|
|
|
67 | (26) |
|
|
|
4.1 Introduction and overview |
|
|
67 | (2) |
|
4.2 The ligands: Wnt proteins, their modification and secretion |
|
|
69 | (1) |
|
4.3 The receptors: Frizzleds and LRPs, multiple receptors and combinations |
|
|
70 | (1) |
|
4.4 Regulation of signalling |
|
|
71 | (8) |
|
4.5 When good signalling goes bad: Wnt signalling in diseases |
|
|
79 | (1) |
|
4.6 Taming the beast: drugs and small molecule inhibitors targeting Wnt signalling |
|
|
80 | (1) |
|
4.7 Conclusion and perspectives |
|
|
81 | (12) |
|
|
|
82 | (11) |
|
5 Mammalian target of rapamycin (mTOR) signalling |
|
|
93 | (22) |
|
|
|
|
|
|
|
93 | (1) |
|
|
|
94 | (5) |
|
5.3 mTOR dysregulation in disease |
|
|
99 | (5) |
|
5.4 Therapeutic opportunities |
|
|
104 | (11) |
|
|
|
107 | (8) |
|
6 c-Met receptor signalling |
|
|
115 | (24) |
|
|
|
6.1 Historical context --- identification of the MET gene |
|
|
115 | (4) |
|
6.2 c-Met expression, activation and signal transduction |
|
|
119 | (2) |
|
6.3 Physiological roles of c-Met |
|
|
121 | (2) |
|
|
|
123 | (5) |
|
6.5 c-Met as a potential therapeutic target in malignancy |
|
|
128 | (2) |
|
|
|
130 | (9) |
|
|
|
130 | (9) |
|
7 Vascular endothelial growth factor and its receptor family |
|
|
139 | (32) |
|
|
|
|
|
|
|
|
|
139 | (1) |
|
|
|
140 | (3) |
|
7.3 Downstream signalling molecules and events |
|
|
143 | (7) |
|
7.4 Signalling regulation |
|
|
150 | (2) |
|
7.5 Dysregulation of signalling in cancer |
|
|
152 | (1) |
|
7.6 Therapeutic opportunities |
|
|
153 | (18) |
|
|
|
158 | (13) |
|
8 Progesterone receptor signalling in breast cancer models |
|
|
171 | (22) |
|
|
|
|
|
|
|
|
|
8.1 Progesterone receptor function |
|
|
172 | (2) |
|
8.2 Model systems: context for studying PR biochemistry |
|
|
174 | (1) |
|
8.3 Progesterone receptor signalling |
|
|
175 | (1) |
|
8.4 Regulation of signalling |
|
|
176 | (5) |
|
8.5 Tissue specific PR actions (breast versus reproductive tract) |
|
|
181 | (2) |
|
8.6 Progesterone receptor and cancer |
|
|
183 | (1) |
|
|
|
183 | (10) |
|
|
|
184 | (9) |
|
|
|
193 | (14) |
|
|
|
|
|
193 | (2) |
|
9.2 Examples of cross-talk |
|
|
195 | (2) |
|
9.3 Convergence of signalling at downstream foci |
|
|
197 | (1) |
|
9.4 Common signalling components |
|
|
198 | (4) |
|
9.5 Compensatory signalling |
|
|
202 | (1) |
|
|
|
203 | (4) |
|
|
|
203 | (4) |
| Index |
|
207 | |
Lisainfo e-raamatute kohta